The market remained flat over the last week, but over the past 12 months, it has risen 18%, with earnings forecast to grow by 16% annually. Investing in penny stocks—though a somewhat outdated term—still highlights opportunities in smaller or newer companies that can offer great value. By focusing on those with robust financials and a clear growth trajectory, investors can find promising opportunities among these lesser-known stocks.

We're going to check out a few of the best picks from our screener tool.

Anavex Life Sciences (AVXL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anavex Life Sciences Corp. is a biopharmaceutical company with a market cap of $254.85 million.

Operations: Anavex Life Sciences Corp. does not report any specific revenue segments.

Market Cap: $254.85M

Anavex Life Sciences, with a market cap of US$254.85 million, is a pre-revenue biopharmaceutical firm facing several challenges typical of penny stocks. Despite being debt-free and having a cash runway exceeding three years, the company remains unprofitable with no significant revenue streams. Recent earnings reports show reduced losses compared to last year, but profitability isn't expected in the near term. The company has faced governance changes and compliance issues with Nasdaq filings, yet it was recently added to multiple Russell indices which may improve visibility among investors. Investor activism is also influencing board dynamics as stakeholders push for changes.

Enovix (ENVX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Enovix Corporation designs, develops, and manufactures lithium-ion battery cells both in the United States and internationally, with a market cap of approximately $889.15 million.

Operations: The company's revenue is primarily generated from its Batteries / Battery Systems segment, which contributed $34.32 million.

Market Cap: $889.15M

Enovix Corporation, with a market cap of approximately US$889.15 million, is navigating the complexities typical of penny stocks. Despite being unprofitable and experiencing increased losses over five years, the company shows promise with its innovative silicon-anode battery technology and strategic executive appointments aimed at scaling production. Recent leadership changes include hiring Dr. Michael Vyvoda as COO to enhance manufacturing capabilities in Malaysia and Korea. Enovix's revenue is forecasted to grow significantly, supported by its new MX-1 platform targeting high-performance applications like drones and defense sectors. The firm maintains a stable cash runway exceeding three years despite high volatility in share price.

SES AI (SES)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SES AI Corporation develops and produces AI-enhanced lithium metal and lithium-ion rechargeable battery technologies for various applications, including electric vehicles and robotics, with a market cap of approximately $199.89 million.

Operations: The company generates revenue from its Batteries / Battery Systems segment, amounting to $21.92 million.

Market Cap: $199.89M

SES AI Corporation, with a market cap of US$199.89 million, faces challenges typical of penny stocks. Despite its innovative AI-enhanced battery technologies, it remains unprofitable and has seen losses grow by 21.5% annually over the past five years. The company's short-term assets exceed both its short and long-term liabilities, providing some financial flexibility. However, SES's stock price volatility is higher than most US stocks, and recent NYSE non-compliance due to low share price adds pressure to regain compliance within six months or consider actions like a reverse stock split. Its inclusion in multiple Russell indexes may offer visibility amid these challenges.

Taking Advantage

• Investigate our full lineup of 339 US Penny Stocks right here.
• Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.